uniQure’s (QURE) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of uniQure (NASDAQ:QURE) in a report published on Monday morning,Benzinga reports. The brokerage currently has a $35.00 target price on the biotechnology company’s stock.

QURE has been the topic of a number of other reports. Mizuho raised shares of uniQure from a “neutral” rating to an “outperform” rating and set a $30.00 target price on the stock in a research note on Thursday, August 14th. Guggenheim reaffirmed a “buy” rating and issued a $28.00 target price on shares of uniQure in a research note on Monday, May 12th. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, August 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of uniQure in a research note on Friday, September 5th. Finally, Cantor Fitzgerald set a $47.00 target price on shares of uniQure in a research note on Wednesday, July 30th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $37.45.

uniQure Trading Down 0.1%

Shares of QURE opened at $17.48 on Monday. The firm’s 50 day simple moving average is $15.19 and its 200 day simple moving average is $13.90. The company has a market capitalization of $959.13 million, a P/E ratio of -4.46 and a beta of 0.14. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98. uniQure has a 1-year low of $4.45 and a 1-year high of $19.18.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.20. The business had revenue of $5.26 million for the quarter, compared to the consensus estimate of $5.00 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. Sell-side analysts forecast that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Buying and Selling at uniQure

In other news, Director Robert Gut sold 3,336 shares of the firm’s stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $48,205.20. Following the transaction, the director owned 56,879 shares in the company, valued at approximately $821,901.55. This trade represents a 5.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jeannette Potts sold 4,670 shares of the firm’s stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $15.14, for a total transaction of $70,703.80. Following the completion of the transaction, the insider owned 115,073 shares in the company, valued at $1,742,205.22. This represents a 3.90% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 22,144 shares of company stock valued at $322,426. 4.79% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in QURE. Northern Trust Corp grew its holdings in shares of uniQure by 2.1% in the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock worth $1,688,000 after purchasing an additional 1,923 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of uniQure by 9.6% in the fourth quarter. BNP Paribas Financial Markets now owns 468,357 shares of the biotechnology company’s stock worth $8,271,000 after purchasing an additional 41,166 shares during the last quarter. Integral Health Asset Management LLC grew its holdings in shares of uniQure by 175.0% in the fourth quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company’s stock worth $19,426,000 after purchasing an additional 700,000 shares during the last quarter. Lighthouse Investment Partners LLC bought a new position in shares of uniQure in the fourth quarter worth approximately $397,000. Finally, Moore Capital Management LP grew its holdings in shares of uniQure by 50.0% in the fourth quarter. Moore Capital Management LP now owns 150,000 shares of the biotechnology company’s stock worth $2,649,000 after purchasing an additional 50,000 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.